This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mujoo, K. Articles by Reisfeld, R. A. Search for Related Content PubMed PubMed Citation Articles by Mujoo, K. Articles by Reisfeld, R. A.

Functional Properties and Effect on Growth Suppression of Human Neuroblastoma Tumors by Isotype Switch Variants of Monoclonal Antiganglioside G_D2 Antibody 14.18¹

Departments of Immunology [K. M., H. M. Y., D. A. C., U. W., D. J. S., R. A. R.] and Basic and Clinical Science [T. J. K.], Scripps Clinic and Research Foundation, La Jolla, California 92037

A complete family of IgG isotype switch variant hybridomas was generated from the anti-G_D2 monoclonal IgG3-producing hybridoma, 14.18, with the aid of the fluorescence-activated cell sorter. The IgG1, IgG2b, and IgG2a monoclonal antibodies (Mabs) produced by respective isotype switch variant hybridomas 14G1, 14G2b, or 14G2a, have binding activities for the biochemically defined G_D2 antigen and G_D2-expressing neuroblastoma target cell lines identical to that of IgG3 Mabs produced by the 14.18 parent cell line. This permitted us to examine the relative in vitro and in vivo cytotoxic capacities of each of the anti-G_D2 antibodies for G_D2-expressing neuroblastoma cells independent of antibody binding affinity or specificity. Mabs produced by 14.18, 14G2a, or 14G2b, but not 14G1, can direct efficient complement-dependent cytotoxicity against neuroblastoma tumor cells in the presence of human complement. Mabs produced by the parent 14.18 or by 14G2a are more efficient in directing antibody-dependent cell-mediated cytotoxicity than Mabs produced by 14G2b, and Mabs of 14G1 are inactive. However, despite these noted in vitro differences, antibodies produced by each member of this switch variant family suppress the growth of human neuroblastoma tumor cells in BALB/c athymic nu/nu mice. These studies suggest that a mechanism(s) other than Fc-directed complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity may account for the in vivo antitumor effects of these particular antibodies.

¹ Supported in part by NIH Grants CA42508 (R. A. R.), AR33489 (T. J. K.), and CA45726 (D. A. C.) and a Fellowship Support Grant from the Joseph Drown Foundation, Los Angeles, CA. This is Scripps Publication No. 5228-IMM.

² Scholar of the Leukemia Society of America and supported in part by the Scott Helping Hand Fund.

³ Recipient of a Fellowship from the National Cancer Center, Plainview, NY.

⁴ To whom requests for reprints should be addressed, at Department of Immunology, Research Institute of Scripps Clinic, 10666 N. Torrey Pines Road, La Jolla, CA 92037.

Received 9/19/88. Revised 2/14/89. Accepted 2/27/89.

This article has been cited by other articles:

				M. Gil, M. Bieniasz, A. Wierzbicki, B. J. Bambach, H. Rokita, and D. Kozbor Targeting a Mimotope Vaccine to Activating Fc{gamma} Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice J. Immunol., November 15, 2009; 183(10): 6808 - 6818. [Abstract] [Full Text] [PDF]

				A. Wierzbicki, M. Gil, M. Ciesielski, R. A. Fenstermaker, Y. Kaneko, H. Rokita, J. T. Lau, and D. Kozbor Immunization with a Mimotope of GD2 Ganglioside Induces CD8+ T Cells That Recognize Cell Adhesion Molecules on Tumor Cells J. Immunol., November 1, 2008; 181(9): 6644 - 6653. [Abstract] [Full Text] [PDF]

				N. Alvarez-Rueda, S. Leprieur, B. Clemenceau, S. Supiot, V. Sebille-Rivain, A. Faivre-Chauvet, F. Davodeau, F. Paris, J. Barbet, J. Aubry, et al. Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen Clin. Cancer Res., September 15, 2007; 13(18): 5613s - 5620s. [Abstract] [Full Text] [PDF]

				M. M. Uttenreuther-Fischer, J. A. Kruger, and P. Fischer Molecular Characterization of the Anti-Idiotypic Immune Response of a Relapse-Free Neuroblastoma Patient following Antibody Therapy: A Possible Vaccine against Tumors of Neuroectodermal Origin? J. Immunol., June 15, 2006; 176(12): 7775 - 7786. [Abstract] [Full Text] [PDF]

				E. Bolesta, A. Kowalczyk, A. Wierzbicki, P. Rotkiewicz, B. Bambach, C.-Y. Tsao, I. Horwacik, A. Kolinski, H. Rokita, M. Brecher, et al. DNA Vaccine Expressing the Mimotope of GD2 Ganglioside Induces Protective GD2 Cross-reactive Antibody Responses Cancer Res., April 15, 2005; 65(8): 3410 - 3418. [Abstract] [Full Text] [PDF]

				T. Simon, B. Hero, A. Faldum, R. Handgretinger, M. Schrappe, D. Niethammer, and F. Berthold Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma J. Clin. Oncol., September 1, 2004; 22(17): 3549 - 3557. [Abstract] [Full Text] [PDF]

				R. Seidenfaden, A. Krauter, F. Schertzinger, R. Gerardy-Schahn, and H. Hildebrandt Polysialic Acid Directs Tumor Cell Growth by Controlling Heterophilic Neural Cell Adhesion Molecule Interactions Mol. Cell. Biol., August 15, 2003; 23(16): 5908 - 5918. [Abstract] [Full Text] [PDF]

				G. Mehes, A. Luegmayr, R. Kornmuller, I. M. Ambros, R. Ladenstein, H. Gadner, and P. F. Ambros Detection of Disseminated Tumor Cells in Neuroblastoma: 3 Log Improvement in Sensitivity by Automatic Immunofluorescence plus FISH (AIPF) Analysis Compared with Classical Bone Marrow Cytology Am. J. Pathol., August 1, 2003; 163(2): 393 - 399. [Abstract] [Full Text] [PDF]

				H. J. Willison and N. Yuki Peripheral neuropathies and anti-glycolipid antibodies Brain, December 1, 2002; 125(12): 2591 - 2625. [Abstract] [Full Text] [PDF]

				C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy Blood, March 15, 2002; 99(6): 2009 - 2016. [Abstract] [Full Text] [PDF]

				S. Engler, C. Thiel, K. Förster, K. David, R. Bredehorst, and H. Juhl A Novel Metastatic Animal Model Reflecting the Clinical Appearance of Human Neuroblastoma: Growth Arrest of Orthotopic Tumors by Natural, Cytotoxic Human Immunoglobulin M Antibodies Cancer Res., April 1, 2001; 61(7): 2968 - 2973. [Abstract] [Full Text]

				M. F. Ozkaynak, P. M. Sondel, M. D. Krailo, J. Gan, B. Javorsky, R. A. Reisfeld, K. K. Matthay, G. H. Reaman, and R. C. Seeger Phase I Study of Chimeric Human/Murine Anti-Ganglioside GD2 Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children's Cancer Group Study J. Clin. Oncol., December 15, 2000; 18(24): 4077 - 4085. [Abstract] [Full Text] [PDF]

				S. C. Helfand, E. B. Dickerson, K. L. Munson, and M. L. Padilla GD3 Ganglioside Antibody Augments Tumoricidal Capacity of Canine Blood Mononuclear Cells by Induction of Interleukin 12 Cancer Res., July 1, 1999; 59(13): 3119 - 3127. [Abstract] [Full Text] [PDF]

				F Mitjans, D Sander, J Adan, A Sutter, J. Martinez, C. Jaggle, J. Moyano, H. Kreysch, J Piulats, and S. Goodman An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice J. Cell Sci., January 8, 1995; 108(8): 2825 - 2838. [Abstract] [PDF]